摘要
In recent years,the management of advanced nonsmall cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutation has developed rapidly.Osimertinib is a third generation EGFR tyrosine kinase inhibitor(TKI),which has achieved satisfactory efficacy and tolerability as the first-line(FLARUA study[ref])and second-line(AURA series of studies[ref])treatment of patients with EGFRmutant NSCLC.This suggested that EGFR signaling is involved in the upregulation of programmed cell death ligand 1(PD-L1)expression,which induces apoptosis of T cells,thereby promoting immune escape of tumor cells[1].